以FXR为核心的胆汁酸代谢机制研究进展
Advanced Progression in the Mechanism of Bile Acid Metabolism Targeting FXR
DOI: 10.12677/HJBM.2018.84008, PDF,  被引量    国家自然科学基金支持
作者: 杨修利, 田思聪, 庞 博, 单毓娟*：哈尔滨工业大学食品科学与工程系，黑龙江 哈尔滨；李宝龙：黑龙江中医药大学药物安全性评价中心，黑龙江 哈尔滨
关键词: 胆汁酸；法尼醇X受体；胆汁酸代谢；Bile Acids； Farnesoid X Receptor； Bile Acid Metabolism
摘要: 胆汁酸是膳食脂质和脂溶性维生素在肠道消化吸收的重要生理因子，同时也可作为信号分子，调节人体内葡萄糖平衡、脂质代谢和能量消耗。胆汁酸代谢紊乱会导致一系列疾病。法尼醇X受体(farnesoid X receptor, FXR)是一种胆汁酸受体，可通过相应靶基因参与多种代谢通路调节，在胆汁酸代谢中发挥重要作用，有望作为治疗胆汁酸代谢紊乱相关疾病的新型药物靶点。本文就FXR在胆汁酸代谢中的调节作用及其机制进行综述，以期为制定胆汁酸代谢紊乱相关疾病的防治策略及其新药研发提供科学依据。
Abstract: Bile acids are important physiological factors that facilitate the digestion & absorption of dietary lipids and fat-soluble vitamins in the gut. In addition, they also act as signaling molecules to regulate glucose homeostasis, lipid metabolism and energy expenditure. Disorders of bile acid metabolism can lead to a series of diseases. The nuclear receptor farnesoid X receptor (FXR) is a specific bile acid receptor which plays an important role in the metabolism of bile acids through the regulation of multiple metabolic pathways and of corresponding target genes. Consequently, FXR is targeted to be a new drug for the therapy of disorders related to bile acid metabolism. This article reviews the recent progressions of FXR in regulating bile acid metabolism and its mechanism, which aims to provide scientific strategies for the prevention/treatment of bile acid metabolic disorders, and new drugs exploration.
文章引用：杨修利, 田思聪, 庞博, 李宝龙, 单毓娟. 以FXR为核心的胆汁酸代谢机制研究进展[J]. 生物医学, 2018, 8(4): 62-68. https://doi.org/10.12677/HJBM.2018.84008

参考文献

[1] Chiang, J.Y.L. (2013) Bile Acid Metabolism and Signaling. Comprehensive Physiology, 3, 1191-1212. [Google Scholar] [CrossRef] [PubMed]
[2] Ferrebee, C.B. and Dawson, P.A. (2015) Metabolic Effects of Intestinal Absorption and Enterohepatic Cycling of Bile Acids. Acta Pharmaceutica Sinica B, 5, 129-134. [Google Scholar] [CrossRef] [PubMed]
[3] Chiang, J.Y.L. (2017) Bile Acid Metabolism and Signaling in Liver Disease and Therapy. Liver Research, 1, 3-9. [Google Scholar] [CrossRef] [PubMed]
[4] Dawson, P.A. and Karpen, S.J. (2015) Intestinal Transport and Metabolism of Bile Acids. The Journal of Lipid Research, 56, 1085-1099. [Google Scholar] [CrossRef] 
[5] 皮宇, 高侃, 朱伟云. 机体胆汁酸肠–肝轴的研究进展[J]. 生理科学进展, 2017, 48(3): 161-166.
[6] De Aguiar Vallim, T.Q., Tarling, E.J. and Edwards, P.A. (2013) Pleiotropic Roles of Bile Acids in Metabolism. Cell Metabolism, 17, 657-669. [Google Scholar] [CrossRef] [PubMed]
[7] Dawson, P.A., Hubbert, M.L. and Rao, A. (2010) Getting the Most from OST: Role of Organic Solute Transporter, OSTα-OSTβ, in Bile Acid and Steroid Metabolism. Biochimica et Biophysica Acta, 1801, 994-1004. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, Y.-K.J., Guo, G.L. and Klaassen, C.D. (2011) Diurnal Variations of Mouse Plasma and Hepatic Bile Acid Concentrations as Well as Expression of Biosynthetic Enzymes and Transporters. PLoS One, 6, e16683. [Google Scholar] [CrossRef] [PubMed]
[9] Wahlström, A., SayinSama, I., Marschall, H.-U., et al. (2016) Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metabolism, 24, 41-50. [Google Scholar] [CrossRef] [PubMed]
[10] Long, S.L., Gahan, C.G.M. and Joyce, S.A. (2017) Interactions between Gut Bacteria and Bile in Health and Disease. Molecular Aspects of Medicine, 56, 54-65. [Google Scholar] [CrossRef] [PubMed]
[11] Jones, B.V., Begley, M., Hill, C., et al. (2008) Functional and Comparative Metagenomic Analysis of Bile Salt Hydrolase Activity in the Human Gut Microbiome. Proceedings of the National Academy of Sci-ences USA, 105, 13580-13585. [Google Scholar] [CrossRef] [PubMed]
[12] Fiorucci, S. and Distrutti, E. (2015) Bile Ac-id-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. Trends in Molecular Medicine, 21, 702-714. [Google Scholar] [CrossRef] [PubMed]
[13] Swann, J.R., Want, E.J., Geier, F.M., et al. (2011) Systemic Gut Microbial Modulation of Bile Acid Metabolism in Host Tissue Compartments. Proceedings of the National Academy of Sciences USA, 108, 4523-4530. [Google Scholar] [CrossRef] [PubMed]
[14] Porez, G., Prawitt, J., Gross, B., et al. (2012) Bile Acid Receptors as Targets for the Treatment of Dyslipidemia and Cardiovascular Disease: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases. The Journal of Lipid Research, 53, 1723-1737. [Google Scholar] [CrossRef] 
[15] Cariello, M., Piccinin, E., Garcia-Irigoyen, O., et al. (2018) Nuclear Receptor FXR, Bile Acids and Liver Damage: Introducing the Progressive Familial Intrahepatic Cholestasis with FXR Mutations. Biochimica et Biophysica Acta, 1864, 1308-1318. [Google Scholar] [CrossRef] [PubMed]
[16] Russell, D.W. (2003) The Enzymes, Regulation, and Genetics of Bile Acid Synthesis. Annual Review of Biochemistry, 72, 137-174. [Google Scholar] [CrossRef] [PubMed]
[17] SayinSama, I., Wahlström, A., Felin, J., et al. (2013) Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metabolism, 17, 225-235. [Google Scholar] [CrossRef] [PubMed]
[18] del Castillo-Olivares, A., Campos, J.A., Pandak, W.M., et al. (2004) The Role of alpha1-Fetoprotein Transcription Factor/LRH-1 in Bile Acid Biosynthesis: A Known Nuclear Receptor Activator That Can Act as a Suppressor of Bile Acid Biosynthesis. The Journal of Biological Chemistry, 279, 16813-16821. [Google Scholar] [CrossRef] 
[19] Zhang, Y., Hagedorn, C.H. and Wang, L. (2011) Role of Nuclear Receptor SHP in Metabolism and Cancer. Biochimica et Biophysica Acta, 1812, 893-908. [Google Scholar] [CrossRef] [PubMed]
[20] Lin, B.C., Wang, M., Blackmore, C., et al. (2007) Liver-Specific Activities of FGF19 Require Klothobeta. The Journal of Biological Chemistry, 282, 27277-27284. [Google Scholar] [CrossRef] 
[21] Holt, J.A., Luo, G., Billin, A.N., et al. (2003) Definition of a Novel Growth Factor-Dependent Signal Cascade for the Suppression of Bile Acid Biosynthesis. Genes & Development, 17, 1581-1591. [Google Scholar] [CrossRef] [PubMed]
[22] Ito, S., Fujimori, T., Furuya, A., et al. (2005) Impaired Negative Feedback Suppression of Bile Acid Synthesis in Mice Lacking beta-Klotho. Journal of Clinical Investigation, 115, 2202-2208. [Google Scholar] [CrossRef] 
[23] Halilbasic, E., Claudel, T. and Trauner, M. (2013) Bile Acid Transporters and Regulatory Nuclear Receptors in the Liver and Beyond. Journal of Hepatology, 58, 155-168. [Google Scholar] [CrossRef] [PubMed]
[24] Zhou, H. and Hylemon, P.B. (2014) Bile Acids Are Nutrient Signaling Hormones. Steroids, 86, 62-68. [Google Scholar] [CrossRef] [PubMed]
[25] Li, T. and Chiang, J.Y.L. (2014) Bile Acid Signaling in Metabolic Disease and Drug Therapy. Pharmacological Reviews, 66, 948-983. [Google Scholar] [CrossRef] [PubMed]
[26] Molinaro, A., Wahlström, A. and Marschall, H.-U. (2018) Role of Bile Acids in Metabolic Control. Trends in Endocrinology & Metabolism, 29, 31-41. [Google Scholar] [CrossRef] [PubMed]
[27] Adorini, L., Pruzanski, M. and Shapiro, D. (2012) Farnesoid X Receptor Targeting to Treat Nonalcoholic Steatohepatitis. Drug Discovery Today, 17, 988-997. [Google Scholar] [CrossRef] [PubMed]
[28] Hirschfield, G.M., Mason, A., Luketic, V., et al. (2015) Efficacy of Obeticholic Acid in Patients with Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholicacid. Gastroenterology, 148, 751-761. [Google Scholar] [CrossRef] [PubMed]
[29] Mudaliar, S., Henry, R.R., Sanyal, A.J., et al. (2013) Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastro-enterology, 145, 574-582. [Google Scholar] [CrossRef] [PubMed]

为你推荐